Evaxion A/S Files November 2025 Form 6-K

Ticker: EVAX · Form: 6-K · Filed: 2025-11-03T00:00:00.000Z

Sentiment: neutral

Topics: regulatory-filing, biotechnology, foreign-issuer

TL;DR

Evaxion A/S filed its monthly 6-K, standard procedure for foreign issuers.

AI Summary

Evaxion A/S, a biotechnology company, filed a Form 6-K on November 3, 2025. This report is for the month of November 2025 and indicates the company is a foreign private issuer filing under the 1934 Securities Exchange Act. Evaxion A/S is incorporated in G7 and has its principal executive offices in Hoersholm, Denmark.

Why It Matters

This filing serves as an update for investors regarding Evaxion A/S's regulatory compliance and corporate information as a foreign private issuer.

Risk Assessment

Risk Level: low — This filing is a routine periodic report and does not contain new material financial or operational information that would typically increase risk.

Key Numbers

Key Players & Entities

FAQ

What type of company is Evaxion A/S?

Evaxion A/S is a biotechnology company specializing in biological products, as indicated by its SIC code 2836.

What is the purpose of a Form 6-K filing?

A Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information to the SEC.

When was this Form 6-K filed?

This Form 6-K was filed on November 3, 2025.

Where are Evaxion A/S's principal executive offices located?

Evaxion A/S's principal executive offices are located at Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark.

Does Evaxion A/S file annual reports under Form 20-F?

Yes, Evaxion A/S indicates it files annual reports under cover of Form 20-F.

From the Filing

0001171843-25-006886.txt : 20251103 0001171843-25-006886.hdr.sgml : 20251103 20251103091509 ACCESSION NUMBER: 0001171843-25-006886 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20251103 FILED AS OF DATE: 20251103 DATE AS OF CHANGE: 20251103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 251442350 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM PROVINCE COUNTRY: G7 BUSINESS PHONE: 4552656554 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM PROVINCE COUNTRY: G7 FORMER COMPANY: FORMER CONFORMED NAME: Evaxion Biotech A/S DATE OF NAME CHANGE: 20201014 6-K 1 f6k_110325.htm FORM 6-K   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File Number: 001-39950 Evaxion A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]      Form 40-F [   ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.  --> INCORPORATION BY REFERENCE This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Press Release On November 3, 2025, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K. Exhibits Exhibit Number   Description       99.1   Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate SI

View on Read The Filing